{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:01:19Z","timestamp":1780365679591,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003789","name":"Helwan University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003789","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Environ Biophys"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypoxia is a condition in which proliferating tumor cells are deprived of oxygen due to limited blood supply from abnormal tumor microvasculature. This study aimed to investigate the molecular changes that occur in tumor cell hypoxia with special emphasis placed on the efficacy of chemotherapeutic and radiation-related effects. Four commercially available chemotherapeutic agents: cisplatin, cyclophosphamide, doxorubicin, and 5-fluorouracil, were tested for their cytotoxic activity on the cancer cell lines PC3 (prostate), HepG2 (liver), and MCF-7 (breast). Tumor cell lines under hypoxia were treated with both IC<jats:sub>50<\/jats:sub> concentrations of the different chemotherapeutic agents and irradiated with 5 and 10\u00a0Gy using a <jats:sup>137<\/jats:sup>Cs gamma source. Hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) protein levels were examined using an ELISA assay. Hypoxic cells showed a significant change in cell viability to all chemotherapeutic agents in comparison to normoxic controls. HepG2 cells were more resistant to the cytotoxic drug doxorubicin compared to other cancer cell lines. The flow cytometric analysis showed that hypoxic cells have lower levels of total apoptotic cell populations (early and late apoptosis) compared to normoxic cells suggesting decreased hypoxia-induced apoptosis in cancer cells. The highest reduction in HIF-1\u03b1 level was observed in the MCF-7 cell line (95.5%) in response to the doxorubicin treatment combined with 10\u00a0Gy irradiation of cells. Chemoradiotherapy could result in minimal as well as a high reduction of HIF-1\u03b1 based on cell type, type of chemotherapy, and amount of ionizing radiation. This study highlights future research work to optimize a combined chemoradiotherapeutic regime in individual cancer cell hypoxia.<\/jats:p>","DOI":"10.1007\/s00411-022-00974-6","type":"journal-article","created":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T05:02:38Z","timestamp":1649480558000},"page":"263-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Radiation and chemotherapy variable response induced by tumor cell hypoxia: impact of radiation dose, anticancer drug, and type of cancer"],"prefix":"10.1007","volume":"61","author":[{"given":"Ayman M.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Nady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhat W.","family":"Shafaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2087-5229","authenticated-orcid":false,"given":"Magdy M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,9]]},"reference":[{"key":"974_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0065304","volume":"8","author":"J Adamski","year":"2013","unstructured":"Adamski J, Price A, Dive C, Makin G (2013) Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1alpha. PLoS ONE 8:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0065304","journal-title":"PLoS ONE"},{"key":"974_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8547846","author":"MA Akanji","year":"2019","unstructured":"Akanji MA, Rotimi D, Adeyemi OS (2019) Hypoxia-inducible factors as an alternative source of treatment strategy for cancer. Oxid Med Cell Longev. https:\/\/doi.org\/10.1155\/2019\/8547846","journal-title":"Oxid Med Cell Longev"},{"key":"974_CR3","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/ijc.29519","volume":"138","author":"K Balamurugan","year":"2016","unstructured":"Balamurugan K (2016) HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer 138:1058\u20131066. https:\/\/doi.org\/10.1002\/ijc.29519","journal-title":"Int J Cancer"},{"key":"974_CR4","first-page":"17","volume":"7","author":"PK Bellamakondi","year":"2014","unstructured":"Bellamakondi PK, Godavarthi A, Ibrahim M, Kulkarni S, Ramachandra Naik M, Sunitha M (2014) In vitro cytotoxicity of Caralluma species by MTT and Trypan Blue dye exclusion. Asian J Pharm Clin Res 7:17\u201319","journal-title":"Asian J Pharm Clin Res"},{"key":"974_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s10555-007-9061-3","volume":"26","author":"RS Bindra","year":"2007","unstructured":"Bindra RS, Crosby ME, Glazer PM (2007) Regulation of DNA repair in hypoxic cancer cells. Cancer Metastasis Rev 26:249\u2013260. https:\/\/doi.org\/10.1007\/s10555-007-9061-3","journal-title":"Cancer Metastasis Rev"},{"key":"974_CR6","first-page":"7106","volume":"60","author":"C Blancher","year":"2000","unstructured":"Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL (2000) Relationship of hypoxia-inducible factor (HIF)-1\u03b1 and HIF-2\u03b1 expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 60:7106\u20137113","journal-title":"Cancer Res"},{"issue":"7","key":"974_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/CAD.0000000000000516","volume":"28","author":"C Bowyer","year":"2017","unstructured":"Bowyer C, Lewis AL, Lloyd AW, Phillips GJ, Macfarlane WM (2017) Hypoxia as a target for drug combination therapy of liver cancer. Anticancer Drugs 28(7):771\u2013780. https:\/\/doi.org\/10.1097\/CAD.0000000000000516","journal-title":"Anticancer Drugs"},{"key":"974_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00109-007-0281-3","volume":"85","author":"MC Brahimi-Horn","year":"2007","unstructured":"Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia and cancer. J Mol Med 85:1301\u20131307","journal-title":"J Mol Med"},{"key":"974_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrc1367","volume":"4","author":"JM Brown","year":"2004","unstructured":"Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4:437\u2013447. https:\/\/doi.org\/10.1038\/nrc1367","journal-title":"Nat Rev Cancer"},{"key":"974_CR10","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1158\/0008-5472.CAN-12-1345","volume":"73","author":"Y Cao","year":"2013","unstructured":"Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CYC, Hanna G, Rich JN, Provenzale JM, Dewhirst MW (2013) Tumor cells upregulate normoxic HIF-1a in response to doxorubicin. Cancer Res 73:6230\u20136242. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-1345","journal-title":"Cancer Res"},{"key":"974_CR11","first-page":"6832","volume":"22","author":"J-Y Chen","year":"2018","unstructured":"Chen J-Y, Zhang Y-G, Du J-D (2018) HIF-1\u03b1 restricts proliferation and apoptosis of Tca8113 cells through up regulation of Hippo signaling pathway under hypoxic conditions. Eur Rev Med Pharmacol Sci 22:6832\u20136837","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"974_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/CMAR.S189445","volume":"11","author":"M Chen","year":"2019","unstructured":"Chen M, Chen LZ, Xu L, Zhang JS, Song X (2019) Neoadjuvant chemoradiation for locally advanced rectal cancer: a systematic review of the literature with network meta-analysis. Cancer Manag Res 11:741\u2013758. https:\/\/doi.org\/10.2147\/CMAR.S189445","journal-title":"Cancer Manag Res"},{"key":"974_CR13","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-08-2127","volume":"15","author":"KL Chi","year":"2009","unstructured":"Chi KL, Zhen FY, Ho DW, Ng MN, Yeoh GCT, Poon RTP, Sheung TF (2009) An Akt\/hypoxia-inducible factor-1\u03b1\/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res 15:3462\u20133471. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2127","journal-title":"Clin Cancer Res"},{"key":"974_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.30918\/IRJMMS.72.19.022","volume":"7","author":"G Davou","year":"2019","unstructured":"Davou G, Chuwang N, Essien U, Choji T, Echeonwu B, Lugos M (2019) Cytotoxicity analysis of etoposide and cisplatin on cell lines from human lung cancer and normal human lung. Int Res J Med Med Sci 7:40\u201347","journal-title":"Int Res J Med Med Sci"},{"key":"974_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5507\/bp.2015.025","volume":"159","author":"H Doktorova","year":"2015","unstructured":"Doktorova H, Hrabeta J, Khalil MA, Eckschlager T (2015) Hypoxia-induced chemoresistance in cancer cells: the role of not only HIF-1. Biomed Pap 159:166\u2013177. https:\/\/doi.org\/10.5507\/bp.2015.025","journal-title":"Biomed Pap"},{"key":"974_CR16","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/cancers11071024","volume":"11","author":"IR Dubbelboer","year":"2019","unstructured":"Dubbelboer IR, Pavlovic N, Heindryckx F, Sj\u00f6gren E, Lennern\u00e4s H (2019) Liver cancer cell lines treated with doxorubicin under normoxia and hypoxia: cell viability and oncologic protein profile. Cancers (Basel) 11:1024. https:\/\/doi.org\/10.3390\/cancers11071024","journal-title":"Cancers (Basel)"},{"key":"974_CR17","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.2147\/IJN.S210731","volume":"14","author":"H Gomari","year":"2019","unstructured":"Gomari H, Moghadam MF, Soleimani M, Ghavami M, Khodashenas S (2019) Targeted delivery of doxorubicin to HER2 positive tumor models. Int J Nanomed 14:5679\u20135690. https:\/\/doi.org\/10.2147\/IJN.S210731","journal-title":"Int J Nanomed"},{"key":"974_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/379088a0","volume":"379","author":"TG Graeber","year":"1996","unstructured":"Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88\u201391. https:\/\/doi.org\/10.1038\/379088a0","journal-title":"Nature"},{"key":"974_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.hjb.2017.08.010","volume":"24","author":"M Herawati","year":"2017","unstructured":"Herawati M, Mulyawan WW, Farhan FS, Ferdinal F, Jusman SWA, Sadikin M (2017) Expression of hypoxia-inducible factor-1\u03b1 and myoglobin in rat heart as adaptive response to intermittent hypobaric hypoxia exposure. HAYATI J Biosci 24:131\u2013135. https:\/\/doi.org\/10.1016\/j.hjb.2017.08.010","journal-title":"HAYATI J Biosci"},{"issue":"5","key":"974_CR20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1586\/erm.09.26","volume":"9","author":"S Huerta","year":"2009","unstructured":"Huerta S, Gao X, Saha D (2009) Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn 9(5):469\u2013480. https:\/\/doi.org\/10.1586\/erm.09.26","journal-title":"Expert Rev Mol Diagn"},{"issue":"27","key":"974_CR21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016167","volume":"98","author":"MS Hung","year":"2019","unstructured":"Hung MS, Wu YF, Chen YC (2019) Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: a meta-analysis and systematic review. Medicine (baltimore) 98(27):e16167","journal-title":"Medicine (baltimore)"},{"key":"974_CR22","doi-asserted-by":"publisher","first-page":"6537","DOI":"10.1158\/0008-5472.CAN-04-0986","volume":"64","author":"LA Huxham","year":"2004","unstructured":"Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI (2004) Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 64:6537\u20136541. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0986","journal-title":"Cancer Res"},{"key":"974_CR23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/2211-5463.12628","volume":"9","author":"A Korga","year":"2019","unstructured":"Korga A, Ostrowska M, Iwan M, Herbet M, Dudka J (2019) Inhibition of glycolysis disrupts cellular antioxidant defense and sensitizes HepG2 cells to doxorubicin treatment. FEBS Open Bio 9:959\u2013972. https:\/\/doi.org\/10.1002\/2211-5463.12628","journal-title":"FEBS Open Bio"},{"key":"974_CR24","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1073\/pnas.0812801106","volume":"106","author":"KA Lee","year":"2009","unstructured":"Lee KA, Qian DZ, Rey S, Wei H, Liu JO, Semenza GL (2009) Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A 106:2353\u20132358. https:\/\/doi.org\/10.1073\/pnas.0812801106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"974_CR25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.7150\/ijbs.15438","volume":"12","author":"Y Li","year":"2016","unstructured":"Li Y, Wang J, Ma X, Li T, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J (2016) A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci 12:1022\u20131031. https:\/\/doi.org\/10.7150\/ijbs.15438","journal-title":"Int J Biol Sci"},{"key":"974_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Fishbane S, Block GA, MacDougall IC (2017) Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 45:187\u2013199. https:\/\/doi.org\/10.1159\/000455166","journal-title":"Am J Nephrol"},{"key":"974_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1159\/000507041","volume":"15","author":"C Matuschek","year":"2020","unstructured":"Matuschek C, Nestle-Kraemling C, K\u00fchn T, Fehm T, B\u00f6lke E, Corradini S, Fastner G, Maas K, Seidel C, Budach W (2020) Neoadjuvant radio (chemo)therapy for breast cancer: an old concept revisited. Breast Care 15:112\u2013117. https:\/\/doi.org\/10.1159\/000507041","journal-title":"Breast Care"},{"key":"974_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20517\/2394-4722.2017.54","volume":"4","author":"DJ McKenna","year":"2018","unstructured":"McKenna DJ, Errington R, Pors K (2018) Current challenges and opportunities in treating hypoxic prostate tumors. J Cancer Metastasis Treat. 4:1\u201313","journal-title":"J Cancer Metastasis Treat."},{"key":"974_CR29","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","volume":"98","author":"IN Mistry","year":"2017","unstructured":"Mistry IN, Thomas M, Calder EDD, Conway SJ, Hammond EM (2017) Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy. Int J Radiat Oncol Biol Phys 98:1183\u20131196. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.03.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"974_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/hp.s93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, Puente P, Azab F, Azab AK (2015) The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia 3:83\u201392. https:\/\/doi.org\/10.2147\/hp.s93413","journal-title":"Hypoxia"},{"key":"974_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.radonc.2005.06.038","volume":"77","author":"M Nordsmark","year":"2005","unstructured":"Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An International Multi-Center Study. Radiother Oncol 77:18\u201324. https:\/\/doi.org\/10.1016\/j.radonc.2005.06.038","journal-title":"Radiother Oncol"},{"key":"974_CR32","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1158\/1078-0432.CCR-14-2298","volume":"21","author":"JK Saggar","year":"2015","unstructured":"Saggar JK, Tannock IF (2015) Chemotherapy rescues hypoxic tumor cells and induces their reoxygenation and repopulation - an effect that is inhibited by the hypoxia-activated prodrug TH-302. Clin Cancer Res 21:2107\u20132114. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2298","journal-title":"Clin Cancer Res"},{"key":"974_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mds3.10064","volume":"3","author":"S Saxena","year":"2020","unstructured":"Saxena S, Agrawal I, Singh P, Jha S (2020) Portable, low-cost hypoxia chamber for simulating hypoxic environments: development, characterization and applications. Med Devices Sensors 3:1\u20138. https:\/\/doi.org\/10.1002\/mds3.10064","journal-title":"Med Devices Sensors"},{"key":"974_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-331","author":"S Strese","year":"2013","unstructured":"Strese S, Frykn\u00e4s M, Larsson R, Gullbo J (2013) Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer. https:\/\/doi.org\/10.1186\/1471-2407-13-331","journal-title":"BMC Cancer"},{"key":"974_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","volume":"9","author":"R Vergis","year":"2008","unstructured":"Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9:342\u2013351. https:\/\/doi.org\/10.1016\/S1470-2045(08)70076-7","journal-title":"Lancet Oncol"},{"key":"974_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijc.20596","volume":"17","author":"M Wartenberg","year":"2003","unstructured":"Wartenberg M, Ling FC, M\u00fcschen M, Klein F, Acker H, Gassmann M, Petrat K, P\u00fctz V, Hescheler J, Sauer H (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia- inducible factor-1 and reactive oxygen species. FASEB J 17:1\u201322. https:\/\/doi.org\/10.1002\/ijc.20596","journal-title":"FASEB J"},{"key":"974_CR37","unstructured":"World Health Organization. Fact sheet no 297. 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs297\/en\/index.html. Accessed 19 Jun 2017"},{"key":"974_CR38","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11:393\u2013410. https:\/\/doi.org\/10.1038\/nrc3064","journal-title":"Nat Rev Cancer"},{"key":"974_CR39","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s10620-008-0296-9","volume":"53","author":"H Xie","year":"2008","unstructured":"Xie H, Song J, Liu K, Ji H, Shen H, Hu S, Yang G, Du Y, Zou X, Jin H, Yan L, Liu J, Fan D (2008) The expression of hypoxia-inducible factor-1\u03b1 in hepatitis B virus-related hepatocellular carcinoma: Correlation with patients\u2019 prognosis and hepatitis B virus X protein. Dig Dis Sci 53:3225\u20133233. https:\/\/doi.org\/10.1007\/s10620-008-0296-9","journal-title":"Dig Dis Sci"},{"key":"974_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-015-0269-y","volume":"15","author":"G Yu","year":"2015","unstructured":"Yu G, Chen X, Chen S, Ye W, Hou K, Liang M (2015) Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms. Cancer Cell Int 15:1\u201312. https:\/\/doi.org\/10.1186\/s12935-015-0269-y","journal-title":"Cancer Cell Int"}],"container-title":["Radiation and Environmental Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00411-022-00974-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00411-022-00974-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00411-022-00974-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T15:11:38Z","timestamp":1650467498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00411-022-00974-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s00411-022-00974-6","relation":{},"ISSN":["0301-634X","1432-2099"],"issn-type":[{"value":"0301-634X","type":"print"},{"value":"1432-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,9]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors disclose that they do not have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}